得乐每日四次与每日两次给药治疗十二指肠溃疡的短期疗效比较。

Comparison of qid and bd administration of De-Nol in the short term treatment of duodenal ulcer.

作者信息

Lazzaroni M, Petrillo M, Bianchi Porro G

出版信息

Br J Clin Pract. 1989 Apr;43(4):151-5.

Abstract

One hundred and twelve patients (80 males, 32 females) with endoscopically proven gastroduodenal ulcer participated in a clinical trial to compare the ulcer-healing effect of colloidal bismuth subcitrate (CBS) at standard dosage, administered either twice daily (Group A) or four times a day (Group B). Endoscopic control was programmed at Week 4 and Week 8, in case of delayed healing. With an 'intention to treat' analysis, the healing percentage at four weeks was 69.6 for Group A and 82.1 for Group B (IC95 of percentage difference: -0.049 to 2.29). At Week 8, the healing percentage for Groups A and B was 87.5 and 94.6 per cent respectively (IC95: -0.05 to 0.19). The mean steady-state values of bismuth levels in plasma were well below the threshold value of 50 micrograms/l. The data confirm the efficacy and acceptability of CBS swallowing formulation tablets and suggest that administration twice daily is an acceptable alternative to the qid schedule.

摘要

112例经内镜证实的胃十二指肠溃疡患者（80例男性，32例女性）参与了一项临床试验，以比较标准剂量的枸橼酸铋钾（CBS）的溃疡愈合效果，该药物分别每日服用两次（A组）或每日服用四次（B组）。若愈合延迟，计划在第4周和第8周进行内镜检查。采用“意向性治疗”分析，A组在4周时的愈合率为69.6%，B组为82.1%（百分比差异的95%置信区间：-0.049至2.29）。在第8周时，A组和B组的愈合率分别为87.5%和94.6%（95%置信区间：-0.05至0.19）。血浆中铋水平的平均稳态值远低于50微克/升的阈值。数据证实了CBS吞咽制剂片的疗效和可接受性，并表明每日服用两次是每日四次给药方案的可接受替代方案。

相似文献

1

Comparison of qid and bd administration of De-Nol in the short term treatment of duodenal ulcer.得乐每日四次与每日两次给药治疗十二指肠溃疡的短期疗效比较。

Br J Clin Pract. 1989 Apr;43(4):151-5.

2

A comparative study of colloidal bismuth subcitrate and cimetidine on the healing and recurrence of duodenal ulcer.枸橼酸铋钾与西咪替丁对十二指肠溃疡愈合和复发影响的对比研究

Scand J Gastroenterol Suppl. 1982;80:23-30.

3

Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.出血性溃疡的抗幽门螺杆菌治疗：比较2天与7天铋剂四联疗法的随机对照试验

Am J Gastroenterol. 1997 Mar;92(3):438-41.

4

[Efficacy of colloid bismuth subcitrate (De-Nol) in gastropathies induced by nonsteroid anti-inflammatory drugs: an open controlled 4-week trial].

Ter Arkh. 2005;77(2):46-9.

5

Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of colloidal bismuth subcitrate (De-Nol).幽门螺杆菌胃炎的治疗：一项使用盐酸哌仑西平（胃疡平）和三种枸橼酸铋钾制剂（得乐）的试点研究。

N Z Med J. 1988 Oct 26;101(856 Pt 1):651-4.

6

[De-nol in NSAID-induced gastroduodenal lesions].[得乐用于非甾体抗炎药引起的胃十二指肠病变]

Minerva Dietol Gastroenterol. 1990 Jan-Mar;36(1):27-30.

7

Colloidal bismuth subcitrate tablets and placebo in chronic duodenal ulceration: a double-blind, randomised trial.枸橼酸铋钾片与安慰剂治疗慢性十二指肠溃疡：一项双盲随机试验

Med J Aust. 1982 Mar 6;1(5):222-3.

8

Likelihood of relapse of duodenal ulcer after initial treatment with cimetidine or colloidal bismuth subcitrate.西咪替丁或枸橼酸铋钾初始治疗后十二指肠溃疡复发的可能性。

Scand J Gastroenterol Suppl. 1982;80:39-42.

9

Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing.比较两种一周三联疗法根除幽门螺杆菌感染及治愈十二指肠溃疡的随机临床试验。

Am J Gastroenterol. 1998 Jan;93(1):35-8. doi: 10.1111/j.1572-0241.1998.035_c.x.

10

[Comparative study of the efficacy of De-Nol and ranitidine in treating duodenal ulcer].[得乐与雷尼替丁治疗十二指肠溃疡疗效的对比研究]

Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1988 Jul-Aug;40(4):375-84.

引用本文的文献

1

Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers.组胺H2受体拮抗剂在消化性溃疡疾病中的应用。治疗消化性溃疡的疗效。

Drugs. 1992 Nov;44(5):709-19. doi: 10.2165/00003495-199244050-00003.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。